Satellos Bioscience Inc.
MSCLF
$0.483
-$0.037-7.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 119.17% | 179.75% | 283.64% | 287.73% | 160.45% |
| Gross Profit | -119.17% | -179.75% | -283.64% | -287.73% | -160.45% |
| SG&A Expenses | 21.70% | 62.48% | 91.02% | 83.97% | 29.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.28% | 126.64% | 187.76% | 171.04% | 77.13% |
| Operating Income | -77.28% | -126.64% | -187.76% | -171.04% | -77.13% |
| Income Before Tax | -74.54% | -96.16% | -79.31% | -91.59% | -36.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.54% | -96.09% | -79.24% | -91.51% | -36.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.54% | -96.09% | -79.24% | -91.51% | -36.56% |
| EBIT | -77.28% | -126.64% | -187.76% | -171.04% | -77.13% |
| EBITDA | -77.23% | -126.91% | -191.85% | -179.21% | -84.54% |
| EPS Basic | -33.09% | -2.31% | 24.54% | 29.40% | 42.59% |
| Normalized Basic EPS | -16.36% | -25.16% | 0.65% | 9.05% | 28.20% |
| EPS Diluted | -33.09% | -2.31% | 24.54% | 29.40% | 42.59% |
| Normalized Diluted EPS | -16.36% | -25.16% | 0.65% | 9.05% | 28.20% |
| Average Basic Shares Outstanding | 32.84% | 64.37% | 129.33% | 174.86% | 142.22% |
| Average Diluted Shares Outstanding | 32.84% | 64.37% | 129.33% | 174.86% | 142.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
